Lv11
30 积分 2023-02-16 加入
Challenges and Opportunities of Emerging Mechanisms of Resistance to KRASG12C Inhibitors
1小时前
已完结
Challenges and Opportunities of Emerging Mechanisms of Resistance to KRASG12C Inhibitors
3天前
已完结
Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D‐NRG1 gene fusion in prostate cancer by data‐drilling a de‐identified tumor database
7天前
已完结
[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2023 edition)]
7天前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
7天前
已完结
Ivonescimab: First Approval
7天前
已完结
Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study
9天前
已完结
Advancing therapy for neuroblastoma
11天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
22天前
已完结
ESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer
23天前
已完结
皖公网安备34019202002308
